Latest Kaiser Health News Stories
Agencies sometimes turn away Medicare beneficiaries with chronic health problems by incorrectly claiming Medicare won’t pay for their services, say patient advocates.
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
Proponents say the proposed regulation will give some consumers more affordable insurance options. Critics warn that the coverage could be less comprehensive.
In this episode of “What The Health?” Julie Rovner of Kaiser Health News, Paige Winfield Cunningham of The Washington Post, Alice Ollstein of Talking Points Memo and Margot Sanger-Katz of The New York Times discuss this week’s news, including release of the administration’s new rules on association health plans, as well as some health-related court rulings and other events that happened around the holidays.
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
These accounts are exempt from taxes and linked to high-deductible health plans. Republicans tried last summer in their unsuccessful efforts to replace the health law to make the accounts more enticing for consumers, but they didn’t make those changes in the current tax bill.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Stephanie Armour of the Wall Street Journal, Alice Ollstein of Talking Points Memo and Margot Sanger Katz of The New York Times discuss new health spending numbers from the federal government, as well as how the year-end legislating in Congress is being complicated by health issues.
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Even though consumers don’t expect to pay for faulty service or goods, they are often forced to pay for bad health care. But a small number of hospitals and doctors are seeking to change that practice.
The House and Senate want to reduce or eliminate federal tax credits for “orphan drugs” used to treat rare diseases, but patients are fighting against the plan.
The price for Pfizer’s Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
Even though the federal health law allows young adults to stay on their parents’ plan, those children are generally responsible for their own debts.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Alice Ollstein of Talking Points Memo and Sarah Jane Tribble of Kaiser Health News discuss some of the under-covered health stories of the past several weeks, including drug price issues, the opioid epidemic and women’s reproductive health.
The federal agents warned store owners that importing drugs from foreign countries is illegal and that those helping “administer” such medicines could face penalties.
Julie Rovner of Kaiser Health News, Sarah Kliff of Vox.com, Joanne Kenen of Politico and Alice Ollstein of Talking Points Memo discuss the inclusion of health policies into the current tax cut debate, including a possible repeal of the fines for people who fail to maintain health insurance.
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor’s office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
UnitedHealth, a health industry goliath, has its hand in doctors’ offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are ‘wannabes.’